Ashkan Delavari
Ashkan Delavari has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Asma Momeni
Department of Anatomical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publicationChangbin Ke
Department of Anesthesiology, Hubei University of Medicine, China
1 shared publication- Fatemeh Sheikhbahaei
Department of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, P. O. Box 76169 13555, Kerman, Iran.
1 shared publication - Tahmineh Mokhtari
Department of Surgery, University of California Davis Medical Center, USA
1 shared publication
Latest Publications
- 3 November 2026
- Published by IGI Global Scientific Publishing
- p. 245-282
Recently Developed Synthetic Inhibitors for Major Depressive Disorder Treatment
Major depressive disorder (MDD) pathophysiology extends beyond traditional monoaminergic mechanisms to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neuroplasticity. This chapter comprehensively reviews emerging synthetic inhibitors targeting these non-monoaminergic pathways. Key therapeutic classes include NLRP3 inflammasome inhibitors, TNF-α antagonists, soluble epoxide hydrolase (sEH) inhibitors, NADPH oxidase (NOX) inhibitors, PARP inhibitors, and modulators of glycogen synthase kinase-3 (GSK-3) and Rho-associated protein kinase (ROCK). Preclinical evidence demonstrates robust efficacy in reversing depression-like behaviors and restoring synaptic plasticity. While several candidates show favorable pharmacokinetic profiles, clinical translation remains limited, necessitating optimized CNS penetration, biomarker-driven trials, and personalized treatment approaches for treatment-resistant depression.
- 3 November 2026
- Published by IGI Global Scientific Publishing
- p. 245-282
Recently Developed Synthetic Inhibitors for Major Depressive Disorder Treatment
Major depressive disorder (MDD) pathophysiology extends beyond traditional monoaminergic mechanisms to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neuroplasticity. This chapter comprehensively reviews emerging synthetic inhibitors targeting these non-monoaminergic pathways. Key therapeutic classes include NLRP3 inflammasome inhibitors, TNF-α antagonists, soluble epoxide hydrolase (sEH) inhibitors, NADPH oxidase (NOX) inhibitors, PARP inhibitors, and modulators of glycogen synthase kinase-3 (GSK-3) and Rho-associated protein kinase (ROCK). Preclinical evidence demonstrates robust efficacy in reversing depression-like behaviors and restoring synaptic plasticity. While several candidates show favorable pharmacokinetic profiles, clinical translation remains limited, necessitating optimized CNS penetration, biomarker-driven trials, and personalized treatment approaches for treatment-resistant depression.